Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Trevena brings in $35mm through its Series B round

Executive Summary

Two-year-old Trevena Inc. (developing GPCR-biased ligand therapeutics for cancer and cardiovascular and neurology conditions) has raised $35mm through its Series B venture round. Current shareholders Polaris Venture Partners and New Enterprise Associates led and were joined by all of Trevena's other existing backers--Alta Partners, Healthcare Ventures, and Yasuda Enterprise Development Co. Trevena will use the money to finish a Phase II trial of TRV120027 for acute heart failure and move other GPCR-biased ligands for pain and inflammation through discovery into the clinic.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies